9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Estimated reading time: < 1 min

Condition: Diffuse Large B-cell Lymphoma

Estimated Enrollment: 300

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Long-term safety profile of tazemetostat measured by number of AEs and duration of exposure to tazemetostat,  The overall survival (OS),  ,

Interventions: Tazemetostat,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: December 2023

Completion Date: April 2024

Last  Posted Date: January 10, 2019

Location: Tucson, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT02875548

Was this article helpful?
Dislike 0